MRK Days sales outstanding
Days sales outstanding at Merck & Co. rose to 66.1 days in fiscal 2025, from 58.5 days in 2024.
Year-end receivables divided by total revenue, times 365. Both inputs as filed.
SOURCE: us-gaap:AccountsReceivableNetCurrent + us-gaap:Revenues · EDGAR CompanyFacts · CIK 310158 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Receivables | Revenue | DSO |
|---|---|---|---|
| FY2025 | $11.8B | $65.0B | 66.1 days |
| FY2024 | $10.3B | $64.2B | 58.5 days |
| FY2023 | $10.3B | $60.1B | 62.8 days |
| FY2022 | $9.4B | $59.3B | 58.2 days |
| FY2021 | $9.2B | $48.7B | 69.2 days |
Cross-checks touching this measure FROM THE FILING REVIEW
✓ MATCHEStotal revenue
Every quoted figure reconciles to the filed lines: $ 65,011 against total revenues; $ 64,168 against total revenues; $ 60,115 against total revenues.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYsales growth
2 of 3 quoted figures reconcile ($65.0 billion against total revenues; 1% against total revenues); 2% does not map to a filed line on this page — carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHReceivables pace
Days sales outstanding moved +7.6 days. Carried as watch; this page verifies no stated cause.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHInventory vs revenue pace
Inventory grew +7.7pp faster than revenue. Carried as watch (7pp threshold).
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Days sales outstanding across coverage → · MRK company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.